Core Insights - Purple Biotech is advancing NT219 in combination with EGFR antibody cetuximab into a Phase 2 study for head and neck cancer [1][3] - The U.S. Patent and Trademark Office has issued a patent for NT219, enhancing its protection in major markets [1][4] - The head and neck cancer treatment market is projected to reach $5 billion by 2030 [3] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance [5] - The company's oncology pipeline includes NT219, CM24, and CAPTN-3, with NT219 being a dual inhibitor targeting IRS1/2 and STAT3 [5] - CM24 has shown promise in a Phase 2 study for pancreatic ductal adenocarcinoma, demonstrating improvement across efficacy endpoints [5] Intellectual Property - The newly issued patent for NT219 in combination with cetuximab completes geographic patent protection in the U.S., Europe, China, and Japan [4] - Purple Biotech's intellectual property portfolio includes a previously issued patent covering NT219 with small molecule EGFR inhibitors [4]
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets